For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the introduction of Tafamidis and Tafamidis meglumine represents a significant advancement . These groundbreaking therapies preserve the transthyretin protein, halting its destructive build-up and alle